UNSPSC 51385605: Fendosal

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C25H19NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9Z709558TZ, chemically known as 5-(4,5-dihydro-2-phenyl-3h-benz(e)indol-3-yl)salicylic acid but generally known as fendosal, which bears US NIH Compound Identifier 40821. European Medicines Agency schedules Fendosal in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07555MIG.

UNSPSC 51385605 Fendosal is a Commodity code that represents pharmaceutical products—specifically fendosal and related drug formulations—but the recent state and local opportunities posted under this code reveal a much broader procurement pattern: state and local health agencies are buying naloxone (opioid overdose reversal kits), safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products through competitive bidding and cooperative purchasing vehicles. The work is transactional procurement of finished pharmaceutical goods for distribution to community health programs, hospital systems, and public health initiatives rather than manufacturing or development services. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and cooperative purchasing alliances serving multiple state and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, which coordinates across Minnesota and Oregon). The procurement mix shows both direct-purchase IFBs for specific pharmaceutical products and exploratory RFIs and RFPs establishing framework agreements with manufacturers and vendors for multi-year distribution networks.

Recent activity spans Florida, Texas, and the upper Midwest (Minnesota and Oregon). Representative solicitations include Seminole County's IFB 60459723LAS (posted June 30, 2026, response due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) gathering market intelligence on direct-to-manufacturer prescription programs to bypass traditional pharmacy benefit managers; and MMCAP's RFP S1070000015802 (posted January 20, 2026, response due March 26, 2026) for generic pharmaceuticals and OTC products through authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), with awards effective July 1, 2026. The MMCAP RFP weights price competitiveness at 75 percent and requires cGMP and Drug Supply Chain Security Act compliance, suggesting cost-driven competition among established pharmaceutical manufacturers with wholesale distribution infrastructure.